Blog

Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background

Sulfisca Therapeutics

Sulfisca Therapeutics, founded by Prof Matt Whiteman, has developed a platform technology of mitochondrial-targeted small molecules for use as therapeutic agents. Sulfisca’s lead compound has been tested and validated across a range of in vivo primary indications with fantastic efficacy, presenting an opportunity to treat conditions with huge unmet medical needs.